Effect of supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of combined vitamins D, K and calcium supplementation on metabolic profiles in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201509015623N51

Enrollment

Registered

2015-09-09

Start date

2015-08-09

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Combined vitamins D- K- calcium tablet, 200 IU vitamin D- 90 µg vitamin K- 500 mg calcium, daily, for 8 weeks orally. Intervention 2: Control group: Placebo tablet,

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria Aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Pregnant woman Elevated levels of prolactin Thyroid disorder Endocrine diseases including diabetes or impaired glucose tolerance, and gastrointestinal problems.

Design outcomes

Primary

Measure	Time frame
Free testosterone. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;FSH. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;LH. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Dehydroepiandrosterone sulfate (DHEAS). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Prolactin. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Free testosterone. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;FSH. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;LH. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Dehydroepiandrosterone sulfate (DHEAS). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Prolactin. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.

—

Secondary

Measure	Time frame
Total antioxidant. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Total antioxidant. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026